|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Wednesday
SATIVEX: GW Pharmaceuticals :
"GW Pharmaceuticals Wednesday announces the start of a second pivotal Phase III trial in people with multiple sclerosis (MS) suffering from central neuropathic pain....This Phase III study is a double-blind randomised placebo-controlled study of Sativex in 218 patients with central neuropathic pain due to MS, who have achieved inadequate pain relief with existing therapies..... |